Beckman Coulter Collaborates in Multisite Research Project for Cardiovascular Disease Markers
The collaborative research will seek to discover genetic signatures for cardiovascular disease and obesity-related hypertension.
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project
Agreement highlights growing interest in novel biology platform that identifies clinical response of cancer drugs.
Buck Institute and Neurobiological Technologies Partner to Develop Treatment for Huntington's Disease
The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties.
IPSOGEN to Undertake Pilot Study on JAK2 Cancer Biomarker with Astrazeneca
The pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.
Vermillion Announces Issuance of U.S. Patent Covering Method for Aiding Diagnosis of Kidney Disorder
The U.S. Patent office has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome.
ImmunoCellular Therapeutics Agrees to Acquire Molecular Antibody Technology
ImmunoCellular has entered into an agreement with Molecular Discoveries covering the IMUC’s acquisition of all monoclonal antibody related technology owned by MDC.
Gamma Medica-Ideas and Mayo Clinic Collaborate on new Breast Cancer Research Project
Multi-site clinical trial to study GM-I’s LumaGEM® Molecular Breast Imaging (MBI) technology for early detection, diagnosis and treatment of breast cancer.
Beckman Coulter to Acquire Flow Cytometry Instrumentation Business from Dako
Beckman Coulter will acquire Dako's research flow cytometry instrumentation business, which is based in Fort Collins, Colorado.
New Targeted Approach to Light-Activated Cancer Drugs
Combining light-activated cancer drugs with tumor-seeking antibodies could provide a more effective way of treating many cancers, according to new research.
Helicos BioSciences Joins Personalized Medicine Coalition
Helicos BioSciences Corporation has joined an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine.